In a session held during the Florida Society of Clinical Oncology’s annual meeting in April, panelist James Almas, MD, vice president and national medical director of clinical effectiveness at LabCorp ...

We examined Medicare national coverage determinations for medical interventions to determine whether or not they have become more restrictive over time. National coverage determinations address ...

The Centers for Medicare and Medicaid Services said this week it's opening a National Coverage Determination analysis, a process that will allow the agency to review and determine whether Medicare ...

CMS plans to end national coverage determinations for artificial hearts, the agency said Wednesday. It also proposed changing how it decides whether to cover ventricular assist devices. Under the plan ...

Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring SAN CARLOS, Calif., Sept.

Coverage determination for oncology drugs can be delayed for months after regulatory approval, a new study suggests. Coverage determination for oncology drugs can be delayed for months after ...

We examined Medicare national coverage determinations for medical interventions to determine whether or not they have become more restrictive over time. National coverage determinations address ...